Detalhe da pesquisa
1.
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers.
Genome Res
; 32(7): 1343-1354, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34933939
2.
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Haematologica
; 109(3): 906-914, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646658
3.
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Cancer
; 129(16): 2491-2498, 2023 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37282609
4.
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
Am J Hematol
; 97(7): 942-950, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35358350
5.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Haematologica
; 2021 08 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34382384
6.
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Eur J Haematol
; 106(2): 230-240, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33107092
7.
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
PLoS Med
; 17(11): e1003323, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33147277
8.
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Br J Haematol
; 189(1): 67-71, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31820442
9.
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Blood
; 132(1): 59-66, 2018 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29784643
10.
Innate Biomineralization.
Int J Mol Sci
; 21(14)2020 Jul 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32650435
11.
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Br J Haematol
; 184(4): 578-593, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30408155
12.
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Blood
; 130(1): 30-34, 2017 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28432222
13.
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Transpl Infect Dis
; 21(2): e13052, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30689291
14.
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Blood
; 128(13): 1735-44, 2016 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-27516441
15.
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Haematologica
; 103(6): 1047-1053, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29567784
16.
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Blood
; 125(24): 3756-9, 2015 Jun 11.
Artigo
Inglês
| MEDLINE | ID: mdl-25943786
17.
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Am J Hematol
; 92(8): 739-745, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28383130
18.
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Am J Hematol
; 97(6): E195-E198, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35285981
19.
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Am J Hematol
; 97(12): E451-E453, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36097868
20.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Am J Hematol
; 97(7): E276-E280, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35472167